WHO's Stance on Hepatitis B Birth Dose Vaccine
The World Health Organization (WHO) emphasizes that the hepatitis B birth dose vaccine is an effective and essential public health intervention. It prevents life-threatening liver disease by stopping mother-to-child transmission at birth. The vaccine has been in use for over three decades, with more than 115 countries including it in their national schedules. Protecting newborns with a timely birth dose provides individual benefit and contributes to national and global elimination efforts.
Concerns Over Guinea-Bissau Trial
WHO has expressed significant concerns regarding a proposed randomized controlled trial (RCT) on the hepatitis B birth dose vaccine in Guinea-Bissau. These concerns relate to the study's scientific justification, ethical safeguards, and alignment with established research principles involving human participants.
Ethical and Scientific Issues Identified
WHO identified several reasons why withholding the vaccine in the trial is considered unethical:
Proven Benefit, Foreseeable Harm
The hepatitis B birth dose vaccine has a proven safety record and is 70–95% effective in preventing mother-to-child transmission. Withholding it exposes newborns to serious, potentially irreversible harm, including chronic infection, cirrhosis, and liver cancer.
No Scientific Necessity for No-Treatment Arm
Placebo or no-treatment vaccine trials are only acceptable when no proven intervention exists or when such a design is indispensable for critical efficacy or safety questions. WHO states neither condition appears to be met.
Insufficient Scientific Justification
Public descriptions indicate the protocol does not question the vaccine's established efficacy but posits hypothetical safety outcomes without credible evidence of a safety signal.
Biased and Low-Utility Design
The described single-blind, no-treatment-controlled design carries a significant likelihood of bias, limiting the interpretability and policy relevance of results.
Exploiting Scarcity
Resource constraints are not considered a justification for withholding proven care in research involving humans. Ethical obligations require minimizing risk and ensuring participant benefit. The protocol, as publicly described, does not appear to ensure minimum harm reduction or benefit, such as screening pregnant women and vaccinating exposed newborns.
WHO concludes that, in its current form and based on public information, the trial is inconsistent with established ethical and scientific principles.
Study Suspension and WHO Support
Guinea-Bissau has suspended the study pending further technical reviews. WHO has stated its readiness to support Guinea-Bissau in its considerations and in accelerating the introduction and strengthening the implementation of the birth dose vaccine through various strategies, including:
- Ensuring birth-dose delivery within 24 hours.
- Antenatal screening for hepatitis B surface antigen (HBsAg) and linkage to care.
- Strengthening cold-chain, logistics, and training for healthcare workers.
- Monitoring timeliness, coverage, and pharmacovigilance for continuous improvement.
WHO reiterates its commitment to ensure newborns worldwide receive timely, evidence-based protection against hepatitis B and that research meets high ethical and scientific standards.